Nurix CFO sells 14,055 shares under 10b5-1 plan

Nurix Therapeutics, Inc.’s Chief Financial Officer Hans van Houte reported open-market sales of company stock.

Rhea-AI Filing Summary

Nurix Therapeutics, Inc.’s Chief Financial Officer Hans van Houte reported open-market sales of company stock. On May 5, 2026, he sold a total of 14,055 shares of common stock in two transactions pursuant to a previously adopted Rule 10b5-1 trading plan.

The reported sales covered 13,473 shares at $16.5756 per share and 582 shares at $17.1751 per share, each representing a weighted average sale price across multiple trades within stated price ranges.

Insider Trade Summary 10b5-1

Net Seller: 14,055 shares

Net Sell 2 txns

Insider van Houte Hans

Role Chief Financial Officer

Sold 14,055 shs ($233K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,473	$16.5756	$223K
Sale	Common Stock	582	$17.1751	$10K

Holdings After Transaction: Common Stock — 37,592 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.11 and the highest price at which shares were sold was $17.10. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. Represents the weighted average sale price. The lowest price at which shares were sold was $17.11 and the highest price at which shares were sold was $17.22. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Key Figures

Total shares sold: 14,055 shares Block sale 1: 13,473 shares at $16.5756 Block sale 2: 582 shares at $17.1751 +2 more

5 metrics

Total shares sold 14,055 shares Common stock sold by CFO on May 5, 2026

Block sale 1 13,473 shares at $16.5756 Weighted average price, open-market sale

Block sale 2 582 shares at $17.1751 Weighted average price, open-market sale

Price range block 1 $16.11–$17.10 Individual trade prices for 13,473-share sale

Price range block 2 $17.11–$17.22 Individual trade prices for 582-share sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale

3 terms

Rule 10b5-1 trading plan financial

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold was $16.11"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nurix Therapeutics (NRIX) disclose?

Nurix Therapeutics disclosed that CFO Hans van Houte sold 14,055 shares of common stock in open-market transactions. The sales occurred on May 5, 2026 and were executed under a previously adopted Rule 10b5-1 trading plan.

How many Nurix Therapeutics (NRIX) shares did the CFO sell and at what prices?

The CFO sold a total of 14,055 Nurix shares. He sold 13,473 shares at a weighted average price of $16.5756 and 582 shares at a weighted average price of $17.1751, with actual trade prices falling within specified ranges.

Were the Nurix Therapeutics (NRIX) CFO’s stock sales pre-planned?

Yes. The filing states the transactions were effected under a previously adopted Rule 10b5-1 trading plan. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio management from discretionary market-timed decisions.

On what date did Nurix Therapeutics (NRIX) CFO sell his shares?

All reported sales by the Nurix CFO occurred on May 5, 2026. The Form 4 lists two non-derivative transactions in common stock on that date, both classified as open-market sales under a Rule 10b5-1 trading plan.

What price ranges applied to the Nurix Therapeutics (NRIX) CFO’s share sales?

For the 13,473-share block, individual trades ranged from $16.11 to $17.10. For the 582-share block, trades ranged from $17.11 to $17.22. The reported transaction prices are weighted averages across these individual executions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 07:53 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van Houte Hans

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		S(1)		13,473	D	$16.5756(2)	38,174	D
Common Stock	05/05/2026		S(1)		582	D	$17.1751(3)	37,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.11 and the highest price at which shares were sold was $17.10. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $17.11 and the highest price at which shares were sold was $17.22. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)